MaxCyte Inc (MXCT) Stock Analysis

AI analysis of MaxCyte Inc (MXCT)

Hold

MaxCyte Inc is currently trading at $1.45, which is 69.4% of its 52-week range, indicating it is closer to its high of $1.80 than its low of $0.64. However, the RSI is at 45.41, suggesting that the stock is neither overbought nor oversold. The company has a forward P/E of 0, reflecting uncertainty in future earnings, and a gross margin of 63.86%, which is relatively strong. The main risk is the negative net income reported, with a loss of $8.87 million in Q2 2026, indicating ongoing financial struggles. Therefore, while there are some positive indicators, the overall financial performance and lack of clear upward momentum suggest holding rather than buying right now.

Valuation Metrics

The current forward P/E ratio for MaxCyte Inc (MXCT) is 0.00, compared to its 5-year average forward P/E of -13.28.

Forward P/E

Overvalued

5Y Average P/E

-13.28

Current P/E

0.00

Overvalued

-3.68

Undervalued

-22.87

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-9.98

Current EV/EBITDA

-3.07

Overvalued

1.46

Undervalued

-21.43

Forward P/S

Undervalued

5Y Average P/S

9.43

Current P/S

3.86

Overvalued

14.36

Undervalued

4.49

Alphio AI Price Scenarios for MXCT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MXCT

$2.88

Scenario price

B

Base

Base · 50%MXCT

$2.21

Scenario price

B

Bear

Bear · 25%MXCT

$1.63

Scenario price

Whales holding MXCT

A

Apollo Global Management, Inc.

+ HoldingMXCT

-2.44%

3M Return

MXCT FAQ — answered by Alphio AI

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

MaxCyte Inc is currently trading at $1.45, which is 69.4% of its 52-week range, indicating it is closer to its high of $1.80 than its low of $0.64. However, the RSI is at 45.41, suggesting that the stock is neither overbought nor oversold. The company has a forward P/E of 0, reflecting uncertainty in future earnings, and a gross margin of 63.86%, which is relatively strong. The main risk is the negative net income reported, with a loss of $8.87 million in Q2 2026, indicating ongoing financial struggles. Therefore, while there are some positive indicators, the overall financial performance and lack of clear upward momentum suggest holding rather than buying right now.